½ÃÀ庸°í¼­
»óǰÄÚµå
1612492

¼¼°èÀÇ º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå : Á¦Ç°º°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(2025-2030³â)

Bare-metal Stents Market by Product (Balloon Catheter, Balloon Expendable Stent, Metallic Stent), End Users (Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, Hospitals) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 185 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀº 2023³â¿¡ 62¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 65¾ï 7,000¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.66%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 91¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º£¾î¸ÞÅ» ½ºÅÙÆ®´Â °ü»ó µ¿¸Æ Áúȯ ȯÀÚÀÇ ÇùÂø ¶Ç´Â Æó»ö µÈ °ü»ó µ¿¸ÆÀ» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. Çʿ伺°ú ÀÀ¿ëÀº ½ÉÇ÷°ü ÁúȯÀÇ Áõ·Ê°¡ Áõ°¡ÇÏ´Â °í·ÉÈ­ »çȸ¿¡¼­ ¸Å¿ì Áß¿äÇϸç, Á¾Á¾ ºñ¿ë Àý°¨°ú Àå±â ÀÌÁß Ç× Ç÷¼ÒÆÇ ¿ä¹ýÀ» ¹ÞÀ» ¼ö¾ø´Â ȯÀÚ¿¡°Ô ÀûÇÕ¼ºÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ÃÖÁ¾ ¿ëµµ´Â º´¿ø, ¿Ü·¡¼ö ¼ö¼ú¼¾ÅÍ, ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç µî ´Ù¹æ¸é¿¡ °ÉÃÄ, ÀÌ·¯ÇÑ ½ºÅÙÆ®´Â ¾àÁ¦ ¿ëÃ⼺ ½ºÅÙÆ®¿¡ ºñÇØ Áï½Ã ÀÔ¼öÇÒ ¼ö ÀÖÀ¸¸ç, »ðÀÔÀÌ ¿ëÀÌÇϱ⠶§¹®¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. È®´ë, ³ëÀÎ Àα¸ Áõ°¡, ¼¼°è¿¡¼­ Áõ°¡ÇÏ´Â ½ÉÀå °ü·Ã Áúȯ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ½ºÅÙÆ® Àç·áÀÇ °³¼±À̶ó´Â ºñÁî´Ï½º ±âȸ ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ ±â¾÷Àº ºñ¿ë È¿À²ÀûÀÎ ½ºÅÙÆ® ¸ðµ¨ÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÓ»ó °á°ú¸¦ °³¼±Çϱâ À§ÇÑ ¿¬±¸ °³¹ß¿¡ ÅõÀÚÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀçÇùÂøÀ²ÀÌ ³·Àº ¾à¹°¿ëÃâ ½ºÅÙÆ®ÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ¾î º£¾î¸ÞÅ»Çü ½ºÅÙÆ®ÀÇ ±×¸²ÀÚ°¡ ¾ã¾ÆÁú ¼ö ÀÖ´Ù´Â °úÁ¦µµ ³²¾Æ ÀÖ½À´Ï´Ù. ÁÖ¸ñ ±â¼ú Çõ½ÅÀ» ÃßÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 3D ÇÁ¸°ÆÃ°ú °°Àº °í±Þ Á¦Á¶ ±â¼úÀ» Ȱ¿ëÇÏ¿© ½ºÅÙÆ® ¹èÄ¡¿¡ À־ÀÇ Ä¿½ºÅ͸¶ÀÌÁ°ú Á¤¹Ðµµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. Á¦Ç°ÀÇ ½Å·Ú¼º°ú ¼ö¿ë¼º °­È­¸¦À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½Ê°ú ¾ö°ÝÇÑ ÀÓ»ó½ÃÇèÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 62¾ï 3,000¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 65¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 91¾ï 7,000¸¸ ´Þ·¯
CAGR(%) 5.66%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ±×¸®°í »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÏ´Â °Í ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ¿ÏÈ­ÇÒ ¼ö ÀÖÀ¸¸ç, ¶ÇÇÑ ¼ÒºñÀÚ Çൿ ±×¸®°í ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°è ½ÉÇ÷°üÁúȯ(CVD) Áõ°¡
    • Àúħ½À Ä¡·á¿¡ÀÇ ±âÈ£ÀÇ °íÁ¶
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå¿¡¼­ÀÇ ´ëüġ·áÀÇ À̿밡´É¼º
  • ½ÃÀå ±âȸ
    • ½ºÅÙÆ®ÀÇ ¼³°è, Àç·á, Á¦Á¶ °øÁ¤¿¡¼­ÀÇ Áö¼ÓÀûÀÎ Áøº¸
    • ÀÇ·á ¼­ºñ½º ¹× ±â¼ú¿¡ ´ëÇÑ ¾×¼¼½º È®´ë¿Í ÇÔ²² °Ç°­ °ü¸® ÁöÃâ Áõ°¡
  • ½ÃÀåÀÇ °úÁ¦
    • ½ºÅÙÆ® À¯Ä¡ÀÇ °ï¶õ°ú ÇÕº´Áõ

Porter's Five Force : º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ȸÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀå ÁýÁß, ´ÜÆíÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¸íÈ®È÷ÇÏ°í º¥´õ´Â °æÀïÀÌ Ä¡¿­ ÇØÁü¿¡ µû¶ó ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°è¿¡¼­ ½ÉÇ÷°üÁúȯ(CVD)ÀÇ ¹ß»ý·üÀÌ »ó½Â
      • Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁø´Ù
    • ¾ïÁ¦¿äÀÎ
      • ½ÃÀå¿¡¼­ÀÇ ´ëüġ·áÀÇ À̿밡´É¼º
    • ±âȸ
      • ½ºÅÙÆ®ÀÇ ¼³°è, Àç·á, Á¦Á¶ °øÁ¤ÀÇ Áö¼ÓÀûÀÎ Áøº¸
      • ÇコÄɾîºñ Áõ°¡¿Í ÀÇ·á ¼­ºñ½º³ª ±â¼ú¿¡ÀÇ ¾×¼¼½ºÀÇ È®´ë
    • °úÁ¦
      • ½ºÅÙÆ® À¯Ä¡ÀÇ ¾î·Á¿ò°ú ÇÕº´Áõ
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Á¦Ç° : ½ÉÀå ¹× ¸»ÃÊ Ç÷°üÀÇ ÀÇ·á Ä¡·á¿¡ dz¼± Ä«Å×ÅÍ ¹× ±Ý¼Ó ½ºÅÙÆ®ÀÇ »ç¿ë
    • ÃÖÁ¾ »ç¿ëÀÚ : º´¿ø¿¡¼­ÀÇ ±ä±Þ °³ÀÔ°ú ¼ö¼ú ÈÄ È¸º¹À»À§ÇÑ º£¾î¸ÞÅ» ½ºÅÙÆ®ÀÇ »ç¿ëÀÌ Áõ°¡
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå : Á¦Ç°º°

  • dz¼± Ä«Å×ÅÍ
  • dz¼± ÀͽºÆæ´õºí ½ºÅÙÆ®
  • ±Ý¼Ó ½ºÅÙÆ®
  • Àڱ⠼ҸðÇü

Á¦7Àå º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç
  • º´¿ø

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ º£¾î¸ÞÅ» ½ºÅÙÆ® ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • FDA°¡ Boston ScientificÀÇ AGENT ¾àÁ¦ ÄÚÆÃ Ç³¼±À» ½ÂÀÎ, ¸»ÃÊ µ¿¸Æ ÁúȯÀÇ Ä¡·á¸¦ °­È­
    • Kaneka Corporation, JMDT»çÀÇ Àμö¿¡ ÀÇÇØ ½ºÅÙÆ® °³¹ß ´É·ÂÀ» °­È­
    • FDA, MedinolÀÇ Çõ½ÅÀûÀÎ ¾àÁ¦ ¿ëÃâ °üµ¿¸Æ ½ºÅÙÆ®¸¦ ½ÂÀÎ
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Abott Laboratories
  • ACE CARDIOPATHY
  • B. Braun SE
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cook Group Incorporated
  • Medtronic PLC
  • MeKo Manufacturing eK
  • Meril Life Sciences Pvt Ltd.
  • MicroPort Scientific Corporation
  • Relisys Medical Devices Limited
  • SLTL Group
  • STENTYS SA
  • Stryker Corporation
  • Terumo Corporation
  • Translumina Therapeutics
JHS 24.12.24

The Bare-metal Stents Market was valued at USD 6.23 billion in 2023, expected to reach USD 6.57 billion in 2024, and is projected to grow at a CAGR of 5.66%, to USD 9.17 billion by 2030.

Bare-metal stents are medical devices used to treat narrowed or blocked coronary arteries in patients with coronary artery disease. They serve as a scaffold to combat artery closure post-angioplasty, enhancing blood flow and preventing restenosis. The necessity and application of bare-metal stents are pivotal in an aging population with increasing cases of cardiovascular ailments, often characterized by their reduced cost and specific suitability in patients who are unable to undergo prolonged dual antiplatelet therapy. End-use spans across hospitals, ambulatory surgical centers, and cardiac catheterization laboratories, where these stents are preferred due to their immediate availability and ease of insertion compared to drug-eluting alternatives. Influential growth drivers include expanding healthcare infrastructure, rising geriatric demographics, and increasing incidences of heart-related disorders across the globe. Opportunities in the market lie in refining stent materials to enhance flexibility and reduce thrombosis rates, along with geographical expansion in emerging markets where healthcare systems are rapidly improving. To exploit these opportunities, firms can focus on developing cost-effective stent models and investing in R&D for improved clinical outcomes. However, challenges persist in stringent regulatory approvals and the growing popularity of drug-eluting stents that offer lower restenosis rates, potentially overshadowing bare-metal variants. Market participants can drive innovation by focusing on biodegradable materials and hybrid stent designs that combine the benefits of both bare-metal and drug-eluting constructs. Moreover, leveraging advanced manufacturing techniques like 3D printing can foster customization and precision in stent deployment. The market's competitive nature underscores the importance of strategic partnerships and pursuing rigorous clinical trials to enhance product credibility and acceptance. Overall, substantial business growth can be achieved through innovation in materials and global market penetration initiatives while navigating regulatory landscapes effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 6.23 billion
Estimated Year [2024] USD 6.57 billion
Forecast Year [2030] USD 9.17 billion
CAGR (%) 5.66%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bare-metal Stents Market

The Bare-metal Stents Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of cardiovascular diseases (CVDs) globally
    • Increasing preference for minimally invasive procedures
  • Market Restraints
    • Availability of alternative treatment in the market
  • Market Opportunities
    • Ongoing advancements in stent design, materials, and manufacturing processes
    • Rising healthcare expenditure, coupled with expanding access to medical services and technologies
  • Market Challenges
    • Difficulties and complications with stent implantation

Porter's Five Forces: A Strategic Tool for Navigating the Bare-metal Stents Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bare-metal Stents Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bare-metal Stents Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bare-metal Stents Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bare-metal Stents Market

A detailed market share analysis in the Bare-metal Stents Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bare-metal Stents Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bare-metal Stents Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bare-metal Stents Market

A strategic analysis of the Bare-metal Stents Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bare-metal Stents Market, highlighting leading vendors and their innovative profiles. These include Abott Laboratories, ACE CARDIOPATHY, B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Medtronic PLC, MeKo Manufacturing e.K., Meril Life Sciences Pvt Ltd., MicroPort Scientific Corporation, Relisys Medical Devices Limited, SLTL Group, STENTYS SA, Stryker Corporation, Terumo Corporation, and Translumina Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Bare-metal Stents Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Balloon Catheter, Balloon Expendable Stent, Metallic Stent, and Self-Expendable.
  • Based on End Users, market is studied across Ambulatory Surgical Centers, Cardiac Catheterization Laboratories, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of cardiovascular diseases (CVDs) globally
      • 5.1.1.2. Increasing preference for minimally invasive procedures
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative treatment in the market
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in stent design, materials, and manufacturing processes
      • 5.1.3.2. Rising healthcare expenditure, coupled with expanding access to medical services and technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulties and complications with stent implantation
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Utilization of balloon catheter and metallic stent in cardiac and peripheral vascular medical procedures
    • 5.2.2. End Users: Increasing usage of bare-metal stents in hospitals for emergency interventions and post-operative recovery
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bare-metal Stents Market, by Product

  • 6.1. Introduction
  • 6.2. Balloon Catheter
  • 6.3. Balloon Expendable Stent
  • 6.4. Metallic Stent
  • 6.5. Self-Expendable

7. Bare-metal Stents Market, by End Users

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Centers
  • 7.3. Cardiac Catheterization Laboratories
  • 7.4. Hospitals

8. Americas Bare-metal Stents Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Bare-metal Stents Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Bare-metal Stents Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA Approves Boston Scientific's AGENT Drug-Coated Balloon, Enhancing Peripheral Artery Disease Treatments
    • 11.3.2. Kaneka Corporation Enhances Stent Development Capabilities with Acquisition of JMDT
    • 11.3.3. FDA Greenlights Medinol's Innovative Drug-Eluting Coronary Stent
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abott Laboratories
  • 2. ACE CARDIOPATHY
  • 3. B. Braun SE
  • 4. Becton, Dickinson and Company
  • 5. BIOTRONIK SE & Co. KG
  • 6. Boston Scientific Corporation
  • 7. Cook Group Incorporated
  • 8. Medtronic PLC
  • 9. MeKo Manufacturing e.K.
  • 10. Meril Life Sciences Pvt Ltd.
  • 11. MicroPort Scientific Corporation
  • 12. Relisys Medical Devices Limited
  • 13. SLTL Group
  • 14. STENTYS SA
  • 15. Stryker Corporation
  • 16. Terumo Corporation
  • 17. Translumina Therapeutics
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦